PTLA Portola Pharmaceuticals Inc

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today reported financial results and provided a corporate update for the quarter ended March 31, 2017.

“During the first quarter of 2017 we continued to focus on regulatory activities for betrixaban and AndexXa™. Our goal is to gain approval for both products this year in the United States and in 2018 in the European Union,” said Bill Lis, chief executive officer of Portola. “Both are highly anticipated by the medical community because they are potentially life-saving medicines in indications where currently there are no approved therapies.”

First Quarter 2017 Financial ResultsCollaboration and license revenue earned under Portola's collaboration and license agreements with Bristol-Myers Squibb Company and Pfizer, Bayer Pharma and Janssen Pharmaceuticals and Daiichi Sankyo was $5.1 million for the first quarter of 2017 compared with $8.3 million for the first quarter of 2016.

Total operating expenses for the first quarter of 2017 were $45.7 million, compared with $73.6 million for the same period in 2016. Total operating expenses for the first quarter of 2017 included $9.0 million in stock-based compensation expense, compared with $7.1 million for the same period in 2016.

Research and development expenses were $30.6 million for the first quarter of 2017, compared with $58.8 million for the first quarter of 2016. The decrease in R&D expenses was largely attributable to the termination of manufacturing activities on the 6x2000 liter, or Line C, manufacturing process in the third quarter of 2016, and decreased program costs related to betrixaban and cerdulatinib.

Selling, general and administrative expenses for the first quarter of 2017 were $15.0 million, compared with $14.8 million for the same period in 2016. For the first quarter of 2017, Portola reported a net loss of $41.7 million, or $0.74 net loss per share, compared with a net loss of $65.0 million, or $1.15 net loss per share, for the same period in 2016. Shares used to compute net loss per share attributable to common stockholders were 56.7 million for the first quarter of 2017, compared with 56.4 million for the same period in 2016.

Cash, cash equivalents and investments at March 31, 2017 totaled $318.2 million, compared with cash, cash equivalents and investments of $318.8 million as of December 31, 2016.

Conference Call Details The live conference call today, Monday, May 8, 2017, at 4:30 p.m. Eastern Time, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765)-507-2588 internationally and using the passcode 8594347. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call. 

About Portola Pharmaceuticals, Inc.     Portola Pharmaceuticals is a biopharmaceutical company developing products that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three investigational programs, including: betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and, cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola also is co-developing Syk-selective inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, anticipated product approvals, the timing of our regulatory events, the potential of our product candidates to advance the field of thrombosis and benefit patients and statements regarding the timing and ability to achieve other milestones and events. Risks that contribute to the uncertain nature of the forward-looking statements include: failure to obtain FDA and/or EMA approval for one or more of our product candidates, regulatory developments in the United States and foreign countries; our expectation that we will incur losses for the foreseeable future and will need additional funds to finance our operations; the accuracy of our estimates regarding our ability to initiate and/or complete our clinical trials and the timing and expense of these trials; the results of our clinical trials related to the efficacy and safety of our product candidates; our potential inability to manufacture our product candidates on a commercial scale in a timely or cost-efficient manner; the accuracy of our estimates regarding expenses and capital requirements; our ability to successfully build a hospital-based sales force and commercial infrastructure; our ability to obtain and maintain intellectual property protection for our product candidates; and our ability to retain key scientific or management personnel. These and other risks and uncertainties are described more fully in our most recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investors:                              Ana Kapor   Portola Pharmaceuticals ir@portola.com         650.246.7431                         

Media: Julie Normart Pure Communications jnormart@purecommunications.com 415.946.1087 

Unaudited Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
	Three Months Ended March 31,
	2017				2016
Collaboration and license revenue	$	5,128			$	8,258
Operating expenses:
Research and development		30,645				58,813
Selling, general and administrative		15,021				14,751
Total operating expenses		45,666				73,564
Loss from operations		(40,538)				(65,306)
Interest and other income,net		413				332
Interest expense		(1,639)				—
Net loss		(41,764)				(64,974)
Net loss attributable to Noncontrolling interest (SRX Cardio)		45				—
Net loss attributable to Portola	$	(41,719)			$	(64,974)
Shares used to compute net loss per share attributable to Portola common stockholders:
Basic and diluted		56,692,788				56,397,881
Net loss per share attributable to Portola common stockholders:
Basic and diluted	$	(0.74)			$	(1.15)

Unaudited Condensed Consolidated Balance Sheet Data
(In thousands)
	2017				2016
	(Unaudited)
Cash, cash equivalents and investments		$	318,197			$	318,771
Prepaid research and development		5,898				7,299
Total current assets		327,581				328,928
Property and equipment, net		5,795				6,143
Intangible asset		3,151				3,151
Prepaid and other long-term assets		4,168				5,214
Total assets		340,695				343,436
Accounts payable		9,487				14,546
Accrued research and development		11,169				23,818
Accrued compensation and other liabilities		3,399				4,806
Deferred revenue (current portion and long-term)		40,635				45,763
Total current liabilities		48,136				65,664
Notes payable, long-term		50,485				49,815
Long term debt		47,803				—
Long term obligation to Collaborator		8,000				8,000
Total liabilities		176,968				150,747
Total stockholders’ equity		161,615				190,532
Noncontrolling interest (SRX Cardio)		2,112				2,157
Total stockholders' equity		163,727				192,689
Total liabilities and stockholders’ equity		340,695				343,436